Finding Neo (antigens, that is)
- 11 July 2019
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 134 (2), 108-109
- https://doi.org/10.1182/blood.2019001334
Abstract
In this issue of Blood, Schischlik et al describe a streamlined analysis of the granulocyte transcriptome (ie, messenger RNA [mRNA]) of 113 patients with myeloproliferative neoplasms (MPNs) to detect potential targets for immunotherapy.This publication has 9 references indexed in Scilit:
- Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasmsBlood, 2019
- Novel treatments to tackle myelofibrosisExpert Review of Hematology, 2018
- Systematic Analysis of Splice-Site-Creating Mutations in CancerCell Reports, 2018
- Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasmsBlood, 2017
- Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometryNature Communications, 2016
- The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasmsLeukemia, 2016
- The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasmsLeukemia, 2016
- Neoantigens in cancer immunotherapyScience, 2015
- Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedCancer Treatment Reviews, 2010